litlas
Log inCreate account

H. Léna

Active 2001–2025

Also published as
H. Lena
51
Papers
21,256
Citations
36
h-index
49
i10-index

Citations

Citations per year for H. Léna2000: 1 citations2001: 1 citations2002: 3 citations2003: 7 citations2004: 8 citations2005: 18 citations2006: 13 citations2007: 22 citations2008: 19 citations2009: 13 citations2010: 19 citations2011: 21 citations2012: 22 citations2013: 38 citations2014: 20 citations2015: 80 citations2016: 430 citations2017: 486 citations2018: 454 citations2019: 1,201 citations2020: 1,226 citations2021: 1,104 citations2022: 815 citations2023: 563 citations2024: 869 citations2025: 418 citations2026: 8 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,667 citing papers, 22% of this breakdownChina: 1,807 citing papers, 14.9% of this breakdownJapan: 789 citing papers, 6.5% of this breakdownFrance: 744 citing papers, 6.1% of this breakdownItaly: 717 citing papers, 5.9% of this breakdownUnited Kingdom: 548 citing papers, 4.5% of this breakdownGermany: 496 citing papers, 4.1% of this breakdownSpain: 493 citing papers, 4% of this breakdownCanada: 373 citing papers, 3.1% of this breakdownSouth Korea: 353 citing papers, 2.9% of this breakdownNetherlands: 330 citing papers, 2.7% of this breakdownSwitzerland: 312 citing papers, 2.6% of this breakdown
0%22%Other 20.7%

Institutions

Fields

  • Medicine83.9%
  • Biochemistry, Genetics and Molecular Biology9.6%
  • Immunology and Microbiology4.7%
  • Engineering0.5%
  • Mathematics0.3%
  • Neuroscience0.2%
  • Other0.8%

Topics

  • Cancer Immunotherapy and Biomarkers19.2%
  • Lung Cancer Treatments and Mutations11.2%
  • Lung Cancer Research Studies9.4%
  • Lung Cancer Diagnosis and Treatment4.6%
  • Immunotherapy and Immune Responses4.4%
  • CAR-T cell therapy research2.8%
  • Other48.4%

Coauthors

All papers

Open in search
  1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

    Authors: H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer - New England Journal of Medicine 2015 cited by 9,459

  2. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    Authors: Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Олександр Войтко, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay Conev, J. Armstrong, Natalie Byrne, Norah J. Shire, Haiyi Jiang, Jonathan W. Goldman, Emilio Batagelj, Ignacio Casarini, Anea Viviana Pastor, S. Sena, Juan José Zarbá, Otto C. Burghuber, Sylvia Hartl, Maximilian J. Hochmair, Bernd Lamprecht, Michael Studnicka, Luís Alberto Schlittler, Fabrício Augusto Martinelli de Oliveira, Aknar Calabrich, Gustavo Girotto, Peo Dos Reis, Carlos Fausto Nino Gorini, Peo Rafael Martins De Marchi, Clarissa Baldotto, Cláudia Vaz de Melo Sette, Mauro Zukin, Nikolay Conev, Assen Dudov, Rumyana Ilieva, Krassimir Koynov, Rositsa Krasteva, Ivan Tonev, Spartak Valev, Violetka Venkova, Minghong Bi, Chengshui Chen, Yuan Chen, Zhendong Chen, Jian Fang, Jifeng Feng, Zhigang Han, Jie Hu, Yi Hu, Xing Li, Zongan Liang, Lin Zhong, Rui Ma, Shenglin Ma, Kejun Nan, Yongqian Shu, Kai Wang, Mengzhao Wang, Gang Wu, Nong Yang, Zhixiong Yang, Helong Zhang, Wei Zhang, Jun Zhao, Yanqiu Zhao, Caicun Zhou, Jianying Zhou, Xiangdong Zhou, Libor Havel, Vı́tězslav Kolek, Leona Koubková, Jaromı́r Roubec, Jana Skřičková, Milada Zemanová, C. Chouaïd, Werner Hilgers, H. Léna, Denis Moro‐Sibilot, G. Robinet, Pierre-Jean Souquet, Jürgen Alt, Helge Bischoff, Christian Grohé, Eckart Laack, Susanne Lang, Jens Panse, Niels Reinmuth, Christian Schulz and 146 more - The Lancet 2019 cited by 2,199

  3. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    Authors: Adrianus J. de Langen, Melissa L. Johnson, Julien Mazières, Anne‐Marie C. Dingemans, Giannis Mountzios, Miklos Pless, Jürgen Wolf, Martin Schüler, H. Léna, Ferdinandos Skoulidis, Yasuto Yoneshima, Sang‐We Kim, Helena Linardou, Silvia Novello, Anthonie J. van der Wekken, Yuanbin Chen, Solange Peters, Enriqueta Felip, Benjamin Solomon, Suresh S. Ramalingam, Christophe Dooms, Colin R. Lindsay, Carlos Gil Ferreira, Normand Blais, Cynthia C. Obiozor, Yang Wang, Bhakti Mehta, Tracy Varrieur, Gataree Ngarmchamnanrith, Björn Stollenwerk, David Waterhouse, Luis Paz‐Ares - The Lancet 2023 cited by 566

  4. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

    Authors: Fabrice Barlési, Julien Mazières, Jean‐Philippe Merlio, D. Debieuvre, Jean Mosser, H. Léna, L’Houcine Ouafik, Benjamin Besse, Isabelle Rouquette, Virginie Westeel, Fabienne Escande, I. Monnet, Antoinette Lemoine, Rémi Veillon, Hélène Blons, Clarisse Audigier-Valette, Pierre‐Paul Bringuier, R. Lamy, Michèle Beau‐Faller, Jean-Louis Pujol, Jean‐Christophe Sabourin, Frédérique Penault‐Llorca, Marc G. Denis, Sylvie Lantuéjoul, Franck Morin, Quân Tran, Pascale Missy, Alexandra Langlais, B. Milleron, J. Cadranel, Jean‐Charles Soria, Gérard Zalcman - The Lancet 2016 cited by 984

  5. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

    Authors: Melissa L. Johnson, Zanete Zvirbule, К. К. Лактионов, Åslaug Helland, Byoung Chul Cho, Vanesa Gutiérrez, Benoît Colinet, H. Léna, M. Wolf, Maya Gottfried, Isamu Okamoto, Cor van der Leest, Patricia Rich, Jen‐Yu Hung, Christina Appenzeller, Zhaowen Sun, David Maag, Yan Luo, Caroline Nickner, Alena Vajikova, Philip Komarnitsky, Jair Bar - Journal of Thoracic Oncology 2021 cited by 156

  6. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Authors: Naiyer A. Rizvi, Julien Mazières, David Planchard, Thomas E. Stinchcombe, Grace K. Dy, Scott Antonia, Leora Horn, H. Léna, Elisa Minenza, B. Mennecier, Gregory A. Otterson, Luis T. Campos, David R. Gandara, Benjamin Levy, Suresh Nair, Gérard Zalcman, Jürgen Wolf, Pierre‐Jean Souquet, Editta Baldini, Federico Cappuzzo, C. Chouaïd, Afshin Dowlati, Rachel E. Sanborn, Ariel López-Chávez, Christian Grohé, Rudolf M. Huber, Christopher Harbison, Christine Baudelet, Brian Lestini, Suresh S. Ramalingam - The Lancet Oncology 2015 cited by 1,429

  7. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

    Authors: Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, H. Léna, Jesus Corral Jaime, Jhanelle E Gray, John D. Powderly, C. Chouaïd, Paolo Bidoli, Paul Wheatley‐Price, Keunchil Park, Ross A. Soo, Yifan Huang, Catherine Wadsworth, Phillip A. Dennis, Naiyer A. Rizvi, Luis Paz-Ares Rodríguez, Silvia Novello, Sandrine Hiret, Peter Schmid, Eckart Laack, Raffaele Califano, Makoto Maemondo, Sang‐We Kim, Jamie E. Chaft, David Vicente Baz, Thierry Berghmans, Dong‐Wan Kim, Veerle Surmont, Martin Reck, Ji‐Youn Han, Esther Holgado Martin, Cristóbal Belda-Iniesta, Yuichiro Oe, Antonio Chella, Akhil Chopra, G. Robinet, Héctor Soto Parrà, Michael J. Thomas, Parneet Cheema, Nobuyuki Katakami, Wu‐Chou Su, Young‐Chul Kim, Juergen Wolf, Jong-Seok Lee, Hideo Saka, Michele Stanislaw Milella, Inmaculada Ramos García, Anne Sibille, Takashi Yokoi, Eun Joo Kang, Shinji Atagi, E. Spaeth-Schwalbe, Makoto Nishio, Fumio Imamura, Nashat Gabrail, Rémi Veillon, Sofie Derijcke, Tadashi Maeda, Dylan M. Zylla, Kendra Kubiak, Armando Santoro, Ma. Noemi Uy, Sarayut Lucien Geater, Antoîne Italiano, Dariusz M. Kowalski, Fabrice Barlési, Yuh‐Min Chen, David R. Spigel, Busyamas Chewaskulyong, Ramón García Gómez, Rosa Álvarez, Chih-Hsin Yang, Te‐Chun Hsia, Fabrice Denis, Hiroshi Sakai, Mark Vincent, Kōichi Goto, Joaquim Bosch‐Barrera, Glen J. Weiss, Jean-Luc Canon, Christian W. Scholz, Massimo Aglietta, Hirotsugu Kemmotsu, Koichi Azuma, Penelope A. Bradbury, Ronald Feld, Abraham Chachoua, Jacek Jassem, Rosalyn A. Juergens, Ramon Palmero Sanchez, Albert Malcolm, Nandagopal Vrindavanam, Kaoru Kubota, Cornelius F. Waller, David Waterhouse, Bruno Coudert, Z. Mark and 52 more - The Lancet Oncology 2018 cited by 576

  8. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

    Authors: Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares, Robin Cornelissen, Nicolas Girard, Elvire Pons‐Tostivint, David Vicente Baz, Shunichi Sugawara, Manuel Cobo, M. Pérol, Céline Mascaux, Elena Poddubskaya, Satoru Kitazono, Hidetoshi Hayashi, Min Hee Hong, Enriqueta Felip, Richard D. Hall, Óscar Juan, Daniel Brungs, Shun Lü, Marina Chiara Garassino, Michael Chargualaf, Yong Zhang, Paul Howarth, Deise Uema, Aaron Lisberg, Jacob Sands, for the TROPION-Lung01 Trial Investigators, Gastón Lucas Martinengo, Juan Puig, Daniel Brungs, Bo Gao, Adnan Nagria, Christos S. Karapetis, Sagun Parakh, Cheol Park, Gaëtan Catala, Frédéric Forget, Sebahat Ocak, Naveen S. Basappa, Geoffrey Liu, Ines B. Menjak, Benjamin Shieh, Shun Lü, Feng Luo, Hongmei Sun, Jialei Wang, Yu Yao, Milada Zemanová, Jaafar Bennouna, Nicolas Girard, Laurent Greillier, Corinne Lamour, H. Léna, Céline Mascaux, Julien Mazières, Denis Moro‐Sibilot, M. Pérol, Elvire Pons‐Tostivint, Virginie Westeel, Akin Atmaca, Christine Greil, Niels Reinmuth, Christian Schumann, Thomas Wehler, Juergen Wolf, James Ho, Csaba Böcskei, Federico Cappuzzo, Filippo de Marinis, Claudia Proto, Manlio Mencoboni, Silvia Novello, Stefania Salvagni, Héctor Soto Parrà, Haruko Daga, Yasushi Goto, Hidetoshi Hayashi, Satoru Kitazono, Kiyotaka Yoh, Ryo Ko, Masashi Kondo, Toshiyuki Kozuki, Takayasu Kurata, Hideaki Mizutani, Kadoaki Ohashi, Satoshi Oizumi, Isamu Okamoto, Satoshi Sakaguchi, H Ozasa, Shunichi Sugawara, Yuichi Tambo, Motohiro Tamiya, Hiroshi Tanaka, Isamu Okamoto, Froylán López-López, Francisco Javier Ramírez Godinez, Jerónimo Rafael Rodríguez Cid, Robin Cornelissen, Steven Gans and 61 more - Journal of Clinical Oncology 2024 cited by 182

  9. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

    Authors: Solange Peters, Jean-Louis Pujol, Urania Dafni, Manuel Dómine, Sanjay Popat, Martin Reck, J. Andrade, A. Becker, Denis Moro‐Sibilot, Alessandra Curioni‐Fontecedro, Olivier Molinier, Kristiaan Nackaerts, A. Insa Mollá, R. Gervais, Guillermo López-Vivanco, J. Madelaine, Julien Mazières, Martin Faehling, Frank Griesinger, Margarita Majem, J.L. González-Larriba, M. Provencio Pulla, Katerina Vervita, Heidi Roschitzki‐Voser, Barbara Ruepp, Paul Mitchell, Rolf A. Stahel, C. Le Péchoux, Dirk De Ruysscher, Rolf A. Stahel, Anita Hiltbrunner, Mariana Pardo-Contreras, A. Gasca-Ruchti, Nino Giacomelli, Roswitha Kammler, Nesa Marti, Rita Pfister, Anne‐Christine Piguet, Susanne Roux, Sandra Troesch, M. Schneider, Robin Schweri, Isabel Zigomo, Zoi Tsourti, Panagiota Zygoura, S. Tsouprou, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Franck Morin, Elodie Amour, G. Mariaule, N. Archirel, María Dolores Arnaiz Fernández, E. Pereira, M. Fernandez, K. Lopez, Ainhoa Hernández, Sarah Chinchen, H. Jurkovic, Alan S. Livingstone, Jerry W. Mitchell, Macie B. Walker, Paul Mitchell, S. Ng, Christopher Steer, Karen Briscoe, Amina Saqib, Ehtesham Abdi, Baerin Houghton, Kenneth J. O’Byrne, B.R. Chittajallu, Brett Hughes, A. Black, Kristiaan Nackaerts, Henrica M.J. Werner, R. Gervais, Gérard Zalcman, F. Vaylet, P. Merle, I. Monnet, Denis Moro‐Sibilot, Olivier Molinier, Nicolas Girard, P.-J. Souquet, Fabrice Barlési, D. Debieuvre, Hélène Senellart, M. Poudenx, A. Dixmier, Damien Pouessel, Jacques Cadranel, H. Léna, Élisabeth Quoix, S. Friard, Clarisse Audigier-Valette, Julien Mazières, Éric Pichon, Martin Faehling and 20 more - Annals of Oncology 2021 cited by 114

  10. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

    Authors: Nathalie Baize, I. Monnet, Laurent Greillier, Margaux Geier, H. Léna, Henri Janicot, A. Vergnenègre, Jacky Créquit, R. Lamy, J.B. Auliac, J. Letreut, H. Le Caer, Radj Gervais, Éric Dansin, Anne Madroszyk, P Renault, G. Le Garff, L. Falchero, H. Bérard, Roland Schött, Patrick Saulnier, C. Chouaïd - The Lancet Oncology 2020 cited by 153

  11. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

    Authors: Élisabeth Quoix, H. Léna, György Losonczy, Frédéric Forget, C. Chouaïd, Zsolt Pápai, Radj Gervais, Christian H. Ottensmeier, Aleksandra Szczęsna, Andrzej Każarnowicz, J. Thaddeus Beck, Virginie Westeel, Enriqueta Felip, D. Debieuvre, Anne Madroszyk, Julien Adam, G Lacoste, Annette Tavernaro, Bérangère Bastien, Céline Halluard, Tania Palanché, Jean‐Marc Limacher - The Lancet Oncology 2015 cited by 207

  12. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

    Authors: Manash Chatterjee, David C. Turner, Enriqueta Felip, H. Léna, Federico Cappuzzo, Leora Horn, Edward B. Garon, Rina Hui, Hendrik‐Tobias Arkenau, Matthew A. Gubens, Matthew D. Hellmann, Dezuo Dong, Chao Li, Kapil Mayawala, Tomoko Freshwater, Malidi Ahamadi, Julie A. Stone, Gregory M. Lubiniecki, J. Zhang, E. Im, Dinesh P. de Alwis, Anna Kondic, Øystein Fløtten - Annals of Oncology 2016 cited by 162

  13. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

    Authors: Élisabeth Quoix, Rodryg Ramlau, Virginie Westeel, Zsolt Pápai, Anne Madroszyk, Alain Rivière, P. Koralewski, Jean-Luc Breton, Erich Stoelben, Denis Braun, D. Debieuvre, H. Léna, Marc Buyse, Marie‐Pierre Chenard, Bruce Acres, G Lacoste, Bérangère Bastien, Annette Tavernaro, Nadine Bizouarne, Jean‐Yves Bonnefoy, Jean‐Marc Limacher - The Lancet Oncology 2011 cited by 265

  14. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)

    Authors: Fabrice Barlési, R. Gervais, H. Léna, J. Hureaux, H. Bérard, D. Paillotin, S. Bota, I. Monnet, Abdesslam Chajara, G. Robinet - Annals of Oncology 2011 cited by 245

  15. High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome

    Authors: Laura Mezquita, Maria Jové, Ernest Nadal, Maria Kfoury, Teresa Morán, Charles Ricordel, Marion Dhooge, Camille Tlemsani, H. Léna, Àlex Teulé, Jose-Valero Álvarez, Judith Raimbourg, Sandrine Hiret, Ludovic Lacroix, Mireia Menéndez, Juana Saldaña, Joan Brunet, P. Lianes, Isabelle Coupier, Édouard Auclin, Gonzalo Recondo, Luc Friboulet, Julien Adam, Emma Green, David Planchard, Thierry Frébourg, Gabriel Capellá, Étienne Rouleau, Conxi Lázaro, Olivier Caron, Benjamin Besse - Journal of Thoracic Oncology 2020 cited by 55

  16. Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

    Authors: Sai‐Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, Ramaswamy Govindan, James Chih‐Hsin Yang, Brett Hughes, H. Léna, Denis Moro‐Sibilot, Alessandra Bearz, Santiago Viteri, Tarek Mekhail, Alexander I. Spira, Walter Bordogna, Bogdana Balas, Peter N. Morcos, Annabelle Monnet, Ali Zeaiter, Dong‐Wan Kim - Journal of Clinical Oncology 2015 cited by 583

  17. Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort

    Authors: Julien Mazières, Gérard Zalcman, Lucio Crinò, Pamela Biondani, Fabrice Barlési, Thomas Filleron, Anne‐Marie C. Dingemans, H. Léna, Isabelle Monnet, Sacha I. Rothschild, Federico Cappuzzo, Benjamin Besse, Luc Thiberville, Damien Rouvière, Rafał Dziadziuszko, Egbert F. Smit, Jürgen Wolf, Christian Spirig, Nicolas Pécuchet, Frauke Leenders, Johannes M. Heuckmann, Joachim Diebold, Julie Milia, Roman K. Thomas, Oliver Gautschi - Journal of Clinical Oncology 2015 cited by 350

  18. A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer

    Authors: Rodryg Ramlau, Élisabeth Quoix, Janusz Rolski, Miklos Pless, H. Léna, Éric Levy, Maciej Krzakowski, Dagmar Hess, Éric Tartour, Marie‐Pierre Chenard, Jean‐Marc Limacher, Nadine Bizouarne, Bruce Acres, Céline Halluard, Thierry Velu - Journal of Thoracic Oncology 2008 cited by 204

  19. Multicentre phase II study of cisplatin–etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study

    Authors: J. Le Treut, M. C. Sault, H. Léna, P.-J. Souquet, A. Vergnenègre, H. Le Caer, H. Bérard, S. Boffa, I. Monnet, Diane Damotte, C. Chouaïd - Annals of Oncology 2013 cited by 176

  20. Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study

    Authors: R. Corre, Laurent Greillier, H. Le Caer, Clarisse Audigier-Valette, Nathalie Baize, H. Bérard, L. Falchero, I. Monnet, Éric Dansin, A. Vergnenègre, M. Marcq, C. Decroisette, J.B. Auliac, Suzanna Bota, R. Lamy, Bartomeu Massutí, C. Dujon, M. Pérol, Jean‐Pierre Daurès, R. Descourt, H. Léna, Carine Plassot, C. Chouaïd - Journal of Clinical Oncology 2016 cited by 407

  21. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial

    Authors: Piero Ferollà, Maria Pia Brizzi, Tim Meyer, Wasat Mansoor, Julien Mazières, Christine Do Cao, H. Léna, Alfredo Berruti, Vincenzo Damiano, Wieneke A. Buikhuisen, Henning Grønbæk, Catherine Lombard‐Bohas, Christian Grohé, Vincenzo Minotti, Marcello Tiseo, Javier De Castro, Nicholas Reed, Gabriella Gislimberti, Neha Singh, Miona Stankovic, Kjell Öberg, Éric Baudin - The Lancet Oncology 2017 cited by 135

  22. Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease

    Authors: Sophie Molet, C. Belleguic, H. Léna, Nicolas Germain, Claude Bertrand, Steven D. Shapiro, Jean‐Michel Planquois, P. Delaval, Vincent Lagente - Inflammation Research 2005 cited by 247

  23. Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort

    Authors: Claire Merveilleux du Vignaux, Éric Dansin, Laurent Mhanna, Laurent Greillier, Éric Pichon, M. Kerjouan, Christelle Clément-Duchêne, B. Mennecier, Virginie Westeel, Marie Robert, Xavier Quantin, Gérard Zalcman, Luc Thiberville, H. Léna, Thierry Jo Molina, Fabien Calcagno, P. Fournel, Julien Mazières, Benjamin Besse, Nicolas Girard - Journal of Thoracic Oncology 2018 cited by 84

  24. LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study

    Authors: M.L. Johnson, A.J. de Langen, D.M. Waterhouse, J. Mazieres, Anne‐Marie C. Dingemans, G. Mountzios, M. Pless, J. Wolf, M. Schuler, H. Lena, F. Skoulidis, I. Okamoto, S-W. Kim, H. Linardou, Silvia Novello, Yueyun Chen, B. Solomon, C. Obiozor, Y. Wang, L. Paz-Ares - Annals of Oncology 2022 cited by 39